|
Lundbeck to acquire Prexton Therapeutics adding foliglurax in clinical phase II to its pipeline of innovative treatments for patients suffering from Parkinson's disease
|
16 March 2018 |
|
Kåre Schultz appointed new president and CEO of Lundbeck
|
06 May 2015 |
|
Lundbeck and Otsuka to co-develop Lu AF20513, an investigational vaccine against Alzheimer's disease
|
15 December 2013 |
|
The solid momentum continues - New Products up by 41%
|
06 November 2013 |
|
Takeda and Lundbeck announce FDA approval of Brintellix™ (vortioxetine)
|
01 October 2013 |
|
Vortioxetine, a new multimodal agent in development for the treatment of major depression
|
23 May 2013 |
|
Lundbeck is well on track to deliver on guidance for 2013
|
01 May 2013 |
|
Lundbeck announces positive results for Brintellix™ (vortioxetine)
|
08 April 2013 |
|
Lundbeck and Otsuka further expand their alliance and enter into collaboration
|
26 March 2013 |
|
Lundbeck on track to meet financial expectations and renew its product portfolio
|
08 August 2012 |
|
Lundbeck's Lu AE58054 meets primary endpoint
|
29 May 2012 |
|
Statistically significant clinical phase III results of Lu AA21004
|
14 May 2012 |
|
Lundbeck and Otsuka Pharmaceutical sign historic agreement
|
13 November 2011 |
|
Lundbeck's third quarter report 2011 - The positive momentum continues
|
10 November 2011 |
|
Lundbeck's first half report 2011
|
11 August 2011 |
|
Lundbeck's partner Mochida receives approval of Lexapro in Japan
|
23 April 2011 |
|
A new pharmaceutical candidate enters Lundbeck's development pipeline
|
30 March 2011 |
|
Lundbeck delivers at the top-end of guidance and momentum is expected to continue in 2011
|
24 February 2011 |
|
The clinical phase III programme commenced on zicronapine
|
20 January 2011 |
|
First two clinical phase III studies confirm the profile of nalmefene
|
03 January 2011 |